Comparing FDA, EMA, and PMDA approaches to chemometric model lifecycle
FDA, EMA, and PMDA all build on ICH Q2(R2) and Q14, but their expectations for routine chemometric model upkeep, post-approval changes, and reference-method failures diverge in ways that shape submission strategy.